.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,646,286

« Back to Dashboard

Details for Patent: 5,646,286

Title: Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines
Abstract:This invention involves a coupling reaction involving an organo-metallic catalyst, preferably a palladium catalyst involving reacting 2-halo-3-hydroxy-6-hydroxymethylpyridine, acrylic acid or its alkali metal salt and benzyl or a phenylalkyl derivative in presence of a dipolar aprotic solvent producing none other than the expected 2-propenoate-3-benzyl or phenylalkylether-6-hydroxymethyl-pyridine product. Said products are converted into medicaments useful for treating psoriasis.
Inventor(s): Sheldrake; Peter William (Tunbridge Wells, GB2), Powling; Laurence Charles (Maidstone, GB2), Bickle; Peter William (Tunbridge Wells, GB2)
Assignee: SmithKline Beecham plc (GB2)
Filing Date:May 26, 1995
Application Number:08/452,200
Claims:1. A process for the preparation of a compound of formula (I): ##STR14## in which n is 1 to 20; R.sup.1 is hydrogen, C.sub.1-6 alkyl or hydroxyC.sub.1-6 alkyl; and R.sup.2 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or trifluoromethyl, which process comprises coupling a compound of formula (II): ##STR15## in which n and R.sup.2 are as defined in formula (I) and R.sup.3 is halogen with a compound of formula (III): ##STR16## in which R.sup.1 is as defined in formula (I) in the presence of palladium catalyst.

2. A process for the preparation of a compound of formula (IA) or a salt or N-oxide thereof: ##STR17## in which: R.sup.1 is hydrogen, benzyl or a group of formula (A): ##STR18## where n is 1 to 20 and R.sup.5 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or trifluoromethyl; m is 0 to 5;

R.sup.8 and R.sup.9 are independently hydrogen, halogen, CO.sub.2 H, C.sub.1-6 alkyl or C.sub.1-6 alkoxy; and

R.sup.10 is a group CR.sup.2 =CR.sup.3 --R.sup.4 or CHR.sup.2 --CHR.sup.3 --R.sup.4 where R.sup.2 and R.sup.3 are independently hydrogen or C.sub.1-6 alkyl and R.sup.4 is cyano or CO.sub.2 R.sup.6 where R.sup.6 is hydrogen or C.sub.1-6 alkyl, which process comprises:

coupling a compound of formula (II): ##STR19## in which R.sup.1 is as defined in formula (IA) and R.sup.7 is a leaving group with a compound of formula (III) or a salt thereof: ##STR20## in which R.sup.2, R.sup.3 and R.sup.4 are as defined in formula (IA) in the presence of a palladium catalyst, to give a compound of formula (I): ##STR21## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined in formula (IA), and thereafter: converting the compound of formula (I) into a compound of formula (IA), or converting a compound of formula (IA) into another compound of formula (IA), or forming a pharmaceutically acceptable salt or N-oxide.

3. A process according to claim 1 in which the palladium coupling is carried out in aqueous DMF.

4. A process according to claim 3 in which R.sup.1 is a group of formula (A) where n is 2 to 8.

5. A process according to claim to 4 in which R.sup.4 is CO.sub.2 R.sup.6 where R.sup.6 is hydrogen or C.sub.1-6 alkyl.

6. A process according to claim 5 in which R.sup.5 is methoxy.

7. A process according to claim 1 in which the compound prepared is: n-butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}prop enoate, methyl 3-[6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}propenoate, methyl 3-{6-hydroxymethyl-3-(phenylethyloxy)pyridin-2-yl}propenoate, t-butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl)propenoate, 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl }propenoic acid, n-butyl 3-{6-hydroxymethyl-3-(phenylethyloxy)pyridin-2-yl}propenoate, ethyl (3-hydroxy-6-methylpyridin-2-yl)propenoate, ethyl 3-{3-hydroxy-6-hydroxymethylpyridin2-yl}propenoate, ethyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate, n-butyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate, methyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate, and and salts and N-oxides thereof.

8. A process according to claim 2 in which the compound of formula (IA) is 3[2-thia-3-[2-(E-2-carboxyethenyl-3-[8-(4-methoxyphenyl)octyloxy]-6-pyridy l]propyl]benzoic acid, [[1-thia-2-[6-(2-carboxyethyl)-5-phenylethyloxy-2-pyridyl]]ethyl]-2,6-dich lorobenzene, or [[1-thia-2-[6-(E-2-carboxyethenyl)-5-phenylethyloxy-2-pyridyl]]ethyl]-2,6- dichlorobenzene, or pharmaceutically acceptable salts or N-oxides thereof.

9. The process of claim 1 wherein the palladium catalyst is palladium (II) catalyst selected from the group consisting of Pd(OAc).sub.2, Pd(OAc).sub.2 /(o-tol).sub.3 P, Pd(OAc).sub.2 / Ph.sub.3 P, Pd(OAc).sub.2 /tri(2-furyl)phosphine, (Ph.sub.3 P).sub.2 PdCl.sub.2, and PdCl.sub.2 /Ph.sub.3 P.

10. The process according to claim 9 wherein the catalyst is bis(triphenylphosphine)palladium dichloride or palladium acetate.

11. The process of claim 2 wherein the palladium catalyst is a palladium (II) catalyst selected from the group consisting of Pd(OAc).sub.2, Pd(OAc).sub.2 /(o-tol).sub.3 P, Pd(OAc).sub.2 /Ph.sub.3 P, Pd(OAc).sub.2 /tri(2-furyl)phosphine, (Ph.sub.3 P).sub.2 PdCl.sub.2, and PdCl.sub.2 /Ph.sub.3 P.

12. The process according to claim 11 wherein the catalyst is bis(triphenylphosphine)palladium dichloride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc